RE-BVS – Piemonte Repository

Sfoglia per AUTORE
CONCA V
Collezione AOU Città della Salute di Torino

Items : 5

Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study. in ESMO open / ESMO Open. 2025 Feb;10(2):104135. doi: 10.1016/j.esmoop.2025.104135. Epub 2025 Feb 4.

2025
AOU Città della Salute di Torino

Antoniotti C; Carullo M; Rossini D; Pietrantonio F; Salvatore L; Lonardi S; Tamberi S; Sciortino C; Conca V; Calegari MA; Ciracì P; Tamburini E; Bergamo F; Boccaccio C; Passardi A; Ritorto G; Ugolini C; Aprile G; Galon J; Cremolini C;

Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2024 Aug 1;42(22):2637-2644. doi: 10.1200/JCO.23.02728. Epub 2024 Jun 12.

2024
AOU Città della Salute di Torino

Antoniotti C; Rossini D; Pietrantonio F; Salvatore L; Lonardi S; Tamberi S; Marmorino F; Moretto R; Prisciandaro M; Tamburini E; Tortora G; Passardi A; Bergamo F; Raimondi A; Ritorto G; Borelli B; Conca V; Ugolini C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Boni L; Galon J; Cremolini C;

Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO. in Clinical colorectal cancer / Clin Colorectal Cancer. 2022 Sep;21(3):220-228. doi: 10.1016/j.clcc.2022.02.003. Epub 2022 Feb 19.

2022
AOU Città della Salute di Torino

Cupini S; Fanchini L; Zaniboni A; Buonadonna A; Tomasello G; Provenzano L; Spagnoletti A; Daniel F; Bergamo F; Germani MM; Conca V; Boccaccino A; Stellato M; Galletti A; Rossini D; Dell'Aquila E; Carlomagno C; Caponnetto S; Rapisardi S; Santini D;

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2022 Jul;23(7):876-887. doi: 10.1016/S1470-2045(22)00274-1. Epub 2022 May 27.

2022
AOU Città della Salute di Torino

Antoniotti C; Rossini D; Pietrantonio F; Catteau A; Salvatore L; Lonardi S; Boquet I; Tamberi S; Marmorino F; Moretto R; Ambrosini M; Tamburini E; Tortora G; Passardi A; Bergamo F; Kassambara A; Sbarrato T; Morano F; Ritorto G; Borelli B; Boccaccino A; Conca V; Giordano M; Ugolini C; Fieschi J; Papadopulos A; Massoué C; Aprile G; Antonuzzo L; et alii...

CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. in British journal of cancer / Br J Cancer. 2021 Sep;125(6):839-845. doi: 10.1038/s41416-021-01483-x. Epub 2021 Jul 12.

2021
AOU Città della Salute di Torino

Cupini S; Fanchini L; Buonadonna A; Ambrosini M; Zaniboni A; Zucchelli G; Caponnetto S; Borelli B; Tomasello G; Marmorino F; Santini D; Antoniotti C; Rasola C; Lonardi S; Conca V; Rossini D; Moretto R; Masi G; Falcone A; Cremolini C;